9月9日周二盘中，港股上市公司荣昌生物（09995.HK）股价大幅上涨13.90%，报110.2港元，创下自2021年12月以来的新高。成交额达4.94亿港元，显示投资者对该股的热烈追捧。
荣昌生物股价飙升的背后，是公司新药研发的重大进展。据悉，公司的重磅新药泰它西普（Telitacicept）用于治疗干燥综合征（又称雪格伦综合征）的上市申请已获国家药品监督管理局药品审评中心（CDE）受理。这一消息进一步增强了市场对荣昌生物研发实力和未来发展前景的信心。
值得注意的是，荣昌生物今年以来的表现格外亮眼。截至目前，该股年内累计涨幅已超过660%，成为港股市场中表现最为出色的股票之一。这一惊人的涨幅反映了投资者对公司在生物制药领域的创新能力和商业潜力的高度认可。随着公司新药研发工作的持续推进，市场普遍看好荣昌生物的长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.